AllenK.B., DowlingR.D., AngellW.W.et al.2004. Transmyocardial revascularization: 5-year follow-up of a prospective, randomized multicenter trial. Ann. Thorac. Surg., 77:1228–1234.
2.
AmanoH., HackettN.R., KanerR.J.et al.2005. Alteration of splicing signals in a genomic/cDNA hybrid VEGF gene to modify the ratio of expressed VEGF isoforms enhances safety of angiogenic gene therapy. Mol. Ther., 12:716–724.
3.
ArkinL.M., SondhiD., WorgallS.et al.2005. Confronting the issues of therapeutic misconception, enrollment decisions, and personal motives in genetic medicine-based clinical research studies for fatal disorders. Hum. Gene Ther., 16:1028–1036.
4.
BostickN.A., SadeR., LevineM.A.et al.2008. Placebo use in clinical practice: report of the American Medical Association Council on Ethical and Judicial Affairs. J. Clin. Ethics, 19:58–61.
5.
CampeauL.1976. Letter: Grading of angina pectoris. Circulation, 54:522–523.
6.
ChuV., KuangJ., McGinnA.et al.1999. Angiogenic response induced by mechanical transmyocardial revascularization. J. Thorac. Cardiovasc. Surg., 118:849–856.
7.
CrystalR.G., HarveyB.G., WisniveskyJ.P.et al.2002. Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum. Gene Ther., 13:65–100.
8.
DekkersW., BoerG.2001. Sham neurosurgery in patients with Parkinson's disease: is it morally acceptable?J. Med. Ethics, 27:151–156.
9.
FinnissD.G., KaptchukT.J., MillerF.et al.2010. Biological, clinical, and ethical advances of placebo effects. Lancet, 375:686–695.
10.
FreedC.R., GreeneP.E., BreezeR.E.et al.2001. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med., 344:710–719.
11.
Gitay-GorenH., SokerS., VlodavskyI.et al.1992. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J. Biol. Chem., 267:6093–6098.
12.
GyongyosiM., KhorsandA., ZaminiS.et al.2005. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation, 112:I157–I165.
13.
HackettN.R., El SawyT., LeeL.Y.et al.2000. Use of quantitative TaqMan real-time PCR to track the time-dependent distribution of gene transfer vectors in vivo. Mol. Ther., 2:649–656.
14.
HarveyB.G., WorgallS., ElyS.et al.1999. Cellular immune responses of healthy individuals to intradermal administration of an E1−E3− adenovirus gene transfer vector. Hum. Gene Ther., 10:2823–2837.
15.
LeeL.Y., PatelS.R., HackettN.R.et al.2000. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann. Thorac. Surg., 69:14–23.
16.
MoldovanN.I., Goldschmidt-ClermontP.J., Parker-ThornburgJ.et al.2000. Contribution of monocytes/macrophages to compensatory neovascularization: the drilling of metalloelastase-positive tunnels in ischemic myocardium. Circ. Res., 87:378–384.
17.
MoseleyJ.B., O'MalleyK., PetersenN.J.et al.2002. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N. Engl. J. Med., 347:81–88.
18.
NathwaniA.C., TuddenhamE.G., RangarajanS.et al.2011. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med., 365:2357–2365.
19.
National Cancer Institute. Surveillance, epidemiology, end results, NCI (2011)www.seer.cancer.gov. 2012 March 20.
20.
ParkJ.E., KellerG.A., FerraraN.1993. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell, 4:1317–1326.
21.
PelletierM.P., GiaidA., SivaramanS.et al.1998. Angiogenesis and growth factor expression in a model of transmyocardial revascularization. Ann. Thorac. Surg., 66:12–18.
22.
PoltorakZ., CohenT., SivanR.et al.1997. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J. Biol. Chem., 272:7151–7158.
23.
RaperS.E., ChirmuleN., LeeF.S.et al.2003. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab., 80:148–158.
24.
RosengartT.K., LeeL.Y., PatelS.R.et al.1999. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation, 100:468–474.
25.
SchnellM.A., ZhangY., TazelaarJ.et al.2001. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol. Ther., 3:708–722.
26.
SchulzK.F., AltmanD.G., MoherD.2010. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ, 340:c332.
27.
SokerS., TakashimaS., MiaoH.Q.et al.1998. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell, 92:735–745.
28.
SquadritoM.L., De PalmaM.2011. Macrophage regulation of tumor angiogenesis: implications for cancer therapy. Mol. Aspects Med., 32:123–145.
29.
StewartD.J., HiltonJ.D., ArnoldJ.M.et al.2006. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatment. Gene Ther., 13:1503–1511.
30.
StewartD.J., KutrykM.J., FitchettD.et al.2009. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol. Ther., 17:1109–1115.
WhitlockP.R., HackettN.R., LeopoldP.L.et al.2004. Adenovirus-mediated transfer of a minigene expressing multiple isoforms of VEGF is more effective at inducing angiogenesis than comparable vectors expressing individual VEGF cDNAs. Mol. Ther., 9:67–75.
